

SOLUTION MATCH

Dompé Pharma is committed to accelerate the development of diagnostic and therapeutic solutions in the field of ophthalmology



Dompé



**SIDE BY SIDE
FOR INNOVATION**

Dompé Farmaceutici & Innovation



Innovation is part of Dompé Farmaceutici's DNA. The company is always looking for project partners sharing its vision for an ecosystem that leverages new ideas and collaborations to develop the therapeutic solutions of the future.

Dompé Farmaceutici is currently bringing together universities, independent researchers, spin-offs and start-ups to promote innovations in two key areas:

- **Ophthalmology**
- **Nutrition & Wellbeing**

With the SIDE BY SIDE FOR INNOVATION program and competition, Dompé Farmaceutici offers knowledge, assets and financial support to boost the co-creation process.

This current Call4Ideas aims to identify new molecules, new targets, but also **new technologies and digital health solutions.**

THE NEED

Dompé Farmaceutici is looking for advanced digital/technological solutions to innovate diagnosis and clinical pathways in ophthalmology.

Environmental factors like the increased use of laptops, phones and tablets drastically affects our visual capacity. And cataracts and macular degeneration are too often diagnosed at too late a stage.

With this call for applications, Dompé aims to overcome the limitations of healthcare systems to improve the early detection of ophthalmic diseases and patients' own monitoring and management of their conditions. The solutions can support healthcare professionals, patients or the relationship between patients and healthcare providers.

Why apply?

- Give your company a chance to integrate a **dynamic ecosystem** that will support you **from ideation to commercialization**
 - Selected initiatives will **receive up to 20 000 EUROS** to boost their development
- The report from this call published through the EU-funded eHealth Hub project will be widely disseminated to the market

SOLUTION REQUIREMENTS

MUST-HAVE requirements:

- Dompé wants to promote any solution using emerging technologies such as digital platforms, Artificial Intelligence, Blockchain or IoT sensors... to accelerate the development of innovation for diagnosis, therapy and disease management in ophthalmology.
- The solutions should have relevant application in the research area.
- This call is aimed at projects that are in the phase of discovery or early stage development (e.g for digital tools, technologies with a technology readiness level or TRL < 6).

NICE-TO-HAVE requirements:

- The solution could allow to build a large scale patient database to better understand market needs.
- The digital solution would be able to monitor patient environment and habits affecting visual capacity (time outdoor/indoor, use of pc, laptop, smartphone, Tvs).
- Eventually , the solution could help monitoring ice chains, drug storage and conservation.

No specific regulatory requirements are requested at that stage.

The Ideal Partner

All start-ups presenting an innovative idea pertaining to the 2 research verticals (nutrition and ophthalmology) will be considered.

The ability of the start-ups to work with academic research groups or those belonging to public and private research centres is a plus.

Possible Business Relationships

Dompé Farmaceutici is open to partnering with any start-up proposing digital solution for ophthalmology. The exact terms of the business relationships will depend on the selected projects, their stages of development and their own business models and objectives.

Desired outcomes:

- Speeding up the diagnosis process
- Improving the access to diagnosis and care
- Enhancing the quality of diagnosis and care
- Supporting patients' monitoring, adherence to therapy and lifestyle changes

PROCESS AND TIMELINE



CALL FOR APPLICATIONS OPENS

28th September 2018



CALL FOR APPLICATIONS CLOSES

31st October 2018



REVIEW OF APPLICATIONS BY DOMPE FARMACEUTICI

End of November 2018



**FINAL FEEDBACK FROM DOMPE FARMACEUTICI
AND SELECTION OF PROGRAMME PARTNERS**

End of December 2018



THE INFORMATION YOU WILL NEED TO APPLY...



APPLY NOW

- ❖ Name of your organization
- ❖ Your main area(s) of activities
- ❖ Your specialization(s)
- ❖ Number of employees
- ❖ Headquarters' location
- ❖ Website URL (or LinkedIn profile)
- ❖ Project Title
- ❖ Brief solution description (max 650 words)
- ❖ Intellectual property overview
- ❖ Development stage of your solution
- ❖ Plans and options to further develop the solution
- ❖ How the 20 000 EUR grant would be used (2 pages)
- ❖ Link to a video presentation (optional)
- ❖ CVs of the team (up to 5)



European eHealth business support

Your contact:

Sylvie Donnasson

Partner, [édito]Health


sylvie@editohealth.com | +33 7 82 49 06 89



BUSINESS MODELLING



ACCESS TO PRIVATE FINANCE



COMMERCIALIZATION



LEGAL & REGULATORY
GUIDANCE

About eHealth Hub:

Boosting The EU Digital Health Ecosystem!

eHealth Hub is an EU-funded project with the mission to provide long-term support to eHealth stakeholders and address key challenges facing European SMEs in that space.

About Solution Match:

Solution Match is one of 5 services offered by eHealth Hub, which focuses on accelerating the commercialization of European digital health solutions.

Working closely with demand-side stakeholders, Solution Match supports care providers, pharma companies, insurance groups and large IT vendors with the scouting and filtering for fit of solutions responding to their very specific needs and requirements.



About **Dompé Farmaceutici**

Dompé is an Italian bio-pharmaceutical company that focuses on innovation, where a long tradition in the field of personal wellness goes hand in hand with a commitment to research and development to meet hitherto unsatisfied therapeutic needs.

Established in 1940 in Milan, Dompé continues to have its headquarters in this city. In Italy, it also has offices in L'Aquila, with an industrial and biotech research hub, and in Naples, where the Company has an R&D division. Dompé also has branches in the United States (in Boston) and in Europe (in Barcelona, Berlin, Paris, Slough (UK) and Tirana).

Dompé is strongly committed to R&D investing every year 15 % of a turnover of around 250 million euro.

Dompé Primary Care operates through two distinct lines - ethical drugs and self-medication. Dompé, with its products offered at over 10,000 pharmacies in Italy, is engaged in the development and distribution of ethical drugs and self-medication, adjuvants, medical devices and cosmetics, and in the fields of vitamin and mineral supplements and personal hygiene. The therapeutic areas include cardiovascular, gastrointestinal, paediatrics, neurology, urology, ophthalmic, stomatology and respiratory.

The Biotech unit is a manifestation of Dompé commitment to meeting unsatisfied patient needs all around the world.

The company pursues this ambitious goal through its commitment to Research and Development in fields characterized by high therapeutic need, using an "open innovation" logic that finds Dompé collaborating with 200 international research centres of excellence in the search for therapeutic solutions to health needs that have yet to be resolved.

The Biotech Unit focuses specifically on the rare diseases field, such as ophthalmology, for instance, an area in which the company has developed and marketed the first ophthalmic product-based on rhNGF (the molecule discovered by Nobel Prize winner Rita Levi Montalcini) for patients suffering from neurotrophic keratitis.